Steven Cohen’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $135M | Buy |
1,587,712
+961,610
| +154% | +$69M | 0.15% | 140 |
|
|
2026
Q1 | $41.3M | Buy |
+626,102
| New | +$39.8M | 0.05% | 455 |
|
|
2025
Q4 | – | Sell |
-471,482
| Closed | -$29.3M | – | 3953 |
|
|
2025
Q3 | $25.9M | Buy |
+471,482
| New | +$19.4M | 0.04% | 467 |
|
|
2025
Q2 | – | Sell |
-1,722,984
| Closed | -$59.9M | – | 2269 |
|
|
2025
Q1 | $69.2M | Buy |
1,722,984
+1,553,071
| +914% | +$71.4M | 0.16% | 158 |
|
|
2024
Q4 | $7.99M | Sell |
169,913
-294,097
| -63% | -$15.3M | 0.02% | 772 |
|
|
2024
Q3 | $24.5M | Buy |
464,010
+89,162
| +24% | +$4.97M | 0.06% | 359 |
|
|
2024
Q2 | $20.3M | Buy |
374,848
+10,139
| +3% | +$612K | 0.05% | 400 |
|
|
2024
Q1 | $25.6M | Buy |
364,709
+207,609
| +132% | +$16.1M | 0.06% | 370 |
|
|
2023
Q4 | $13.1M | Buy |
+157,100
| New | +$5.69M | 0.03% | 596 |
|
|
2023
Q3 | – | Sell |
-160,400
| Closed | -$5.34M | – | 2534 |
|
|
2023
Q2 | $5.23M | Buy |
+160,400
| New | +$5.93M | 0.02% | 803 |
|
|
2023
Q1 | – | Sell |
-271,500
| Closed | -$12.4M | – | 2293 |
|
|
2022
Q4 | $12.4M | Buy |
271,500
+239,500
| +748% | +$10.3M | 0.04% | 481 |
|
|
2022
Q3 | $1.55M | Buy |
32,000
+12,367
| +63% | +$595K | 0.01% | 983 |
|
|
2022
Q2 | $771K | Sell |
19,633
-1,602,967
| -99% | -$64.5M | ﹤0.01% | 1127 |
|
|
2022
Q1 | $59.7M | Buy |
1,622,600
+737,146
| +83% | +$26.2M | 0.24% | 118 |
|
|
2021
Q4 | $40.4M | Sell |
885,454
-123,846
| -12% | -$4.78M | 0.16% | 169 |
|
|
2021
Q3 | $36.1M | Buy |
1,009,300
+681,800
| +208% | +$20.1M | 0.16% | 161 |
|
|
2021
Q2 | $6.48M | Sell |
327,500
-47,100
| -13% | -$1.11M | 0.03% | 548 |
|
|
2021
Q1 | $8.71M | Sell |
374,600
-791,694
| -68% | -$16.9M | 0.04% | 457 |
|
|
2020
Q4 | $24.2M | Sell |
1,166,294
-440,056
| -27% | -$8.04M | 0.12% | 237 |
|
|
2020
Q3 | $34.8M | Buy |
1,606,350
+1,278,073
| +389% | +$29.9M | 0.18% | 153 |
|
|
2020
Q2 | $7.74M | Sell |
328,277
-462,923
| -59% | -$8.68M | 0.05% | 393 |
|
|
2020
Q1 | $9.33M | Sell |
791,200
-2,237,551
| -74% | -$28.5M | 0.08% | 315 |
|
|
2019
Q4 | $32.1M | Buy |
3,028,751
+2,594,651
| +598% | +$26.7M | 0.17% | 178 |
|
|
2019
Q3 | $4.94M | Sell |
434,100
-172,900
| -28% | -$2.17M | 0.03% | 461 |
|
|
2019
Q2 | $6.83M | Buy |
+607,000
| New | +$5.85M | 0.04% | 449 |
|
Other funds holding CYTK
Steven Cohen's CYTK Position: Q2 2026 in Review
Steven Cohen increased its Cytokinetics (CYTK) stake by 154% in Q2 2026, buying an estimated $69M and bringing the position to 1,587,712 shares worth $135M. The position accounts for 0.15% of the portfolio, ranked #140.
Steven Cohen first reported a position in CYTK in Q2 2019 and has held it in 25 quarters since. 486 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Steven Cohen held 1,587,712 shares of Cytokinetics worth $135M as of Q2 2026.
- Steven Cohen bought 961,610 Cytokinetics shares in Q2 2026, an estimated $69M.
- Cytokinetics made up 0.15% of Steven Cohen's portfolio in Q2 2026, its #140 holding.
- Steven Cohen first reported a position in Cytokinetics in Q2 2019 and has held it in 25 quarters since.
- 486 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.